Risk of severe (Grade 3-4) vascular thromboembolic adverse events related to anti-EGFR monoclonal antibodies (cetuximab and panitumumab) regimens administered in solid tumours: a meta-analysis of randomized controlled clinical trials
收藏官方服务：
资源简介：
Systematic review protocol registration
创建时间：
2015-08-06
